FDA
-
-
-
-
-
-
-
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) Reports FY23, Provides Business Update
-
-
-
-
-
-
-
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
-
-
-
-
-
-
-
TransCode Therapeutics Reports 2022 Results; Provides Business Update
-
-
-
-
-
-
-
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
-
-
-
-
-
-
-
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
-
-
-
-
-
-
-
CORRECTION --TransCode Therapeutics
-
330,199 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

